Recommendations for Prostate Cancer Survivorship Care: An Update to the 2009 Michigan Cancer Consortium Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae
Restricted accessReview articleFirst published online September, 2014
Recommendations for Prostate Cancer Survivorship Care: An Update to the 2009 Michigan Cancer Consortium Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae
Primary care providers inevitably care for prostate cancer survivors. However, few comprehensive resources exist to aid them in providing the most up-to-date and evidence-based care. To meet this clinical need, we examined and updated the Michigan Cancer Consortium prostate cancer survivorship guidelines.
Methods:
Using an expert panel and focus groups comprised of prostate cancer stakeholders, we updated the Michigan Cancer Consortium's 2009 Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae.
Results:
The guideline recommendations were modified to serve as a point-of-care resource and to facilitate care transitions between specialty and primary care. The modified recommendations were approved by the Michigan Cancer Consortium and now include the following elements: (1) patient-reported symptom assessment, (2) distinctions between medical and self-management strategies for prostate cancer treatment-related side effects, (3) recommendations for involving partners in survivorship care, and (4) care coordination strategies for primary and specialty care providers. Online guidance for medical therapy and self-management resources are also provided.
Conclusions:
To remedy a persistent lack of guidance to direct prostate cancer survivorship care in the primary care setting, the updated Michigan Cancer Consortium prostate cancer survivorship tools convert a static guideline into a dynamic resource to improve outcomes and support coordination among primary care providers, cancer specialists, patients, and caregivers.
Get full access to this article
View all access options for this article.
References
1.
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) program. Available at www.seer.cancer.gov Last accessed June3, 2014.
2.
SandaMG, DunnRL, MichalskiJ, et al.Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med, 2008; 358:1250–1261.
3.
SkolarusTA, MillerDC, ZhangY, HollingsworthJM, HollenbeckBK. The delivery of prostate cancer care in the United States: implications for delivery system reform. J Urol, 2010; 184:2279–2284.
4.
SkolarusTA, Holmes-RovnerM, NorthouseLL, et al.Primary care perspectives on prostate cancer survivorship: Implications for improving quality of care. Urol Oncol, 2013; 31:727–732.
5.
Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition. The National Academies Press: Washington, DC, 2005.
6.
Michigan Cancer Consortium Prostate Cancer Action Committee. Guidelines for primary care management of prostate cancer post-treatment sequelae. Available at www.prostatecancerdecision.org Last accessed June3, 2014.
7.
SzymanskiKM, WeiJT, DunnRL, SandaMG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology, 2010; 76:1245–1250.
8.
ChangP, SzymanskiKM, DunnRL, et al.Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol, 2011; 186:865–872.
9.
NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, Version 2.2014. Copyright National Comprehensive Cancer Network, Inc. Available at www.nccn.org/professionals/physician_gls/pdf/prostate.pdf Last accessed June3, 2014.
10.
CooksonMS, AusG, BurnettAL, et al.Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol, 2007; 177:540–545.
ThompsonI, ThrasherJB, AusG, et al.Guideline for the management of clinically localized prostate cancer: 2007 Update. J Urol, 2007; 177:2106–2131.
13.
RoachM3rd, HanksG, ThamesHJr., et al.Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys, 2006; 65:965–974.
14.
RayME, ThamesHD, LevyLB, et al.PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys, 2006; 64:1140–1150.
15.
NishiyamaT. Serum testosterone levels after medical or surgical androgen deprivation: A comprehensive review of the literature. Urol Oncol, 2014; 32:38.e17–28.
16.
MillerDC, SandaMG, DunnRL, et al.Long-term outcomes among localized prostate cancer survivors: Health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol, 2005; 23:2772–2780.
17.
MichaelsonMD, CotterS, GargolloP, ZietmanA, DahlD, SmithM. Management of complications of prostate cancer treatment. CA, 2008; 58:196–213.
18.
ZelefskyMJ, YamadaY, PeiX, et al.Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology, 2011; 77:986–990.
19.
KeyesM, MillerS, MoravanV, et al.Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys, 2009; 73:1023–1032.
20.
KaoTC, CruessDF, GarnerD, et al.Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. J Urol, 2000; 163:858–864.
21.
FicarraV, NovaraG, ArtibaniW, et al.Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol, 2009; 55:1037–1063.
22.
GoodePS, BurgioKL, JohnsonTM, 2nd, et al. Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial. JAMA, 2011; 305:151–159.
23.
BauerRM, BastianPJ, GozziC, StiefCG. Postprostatectomy incontinence: All about diagnosis and management. Eur Urol, 2009; 55:322–333.
24.
HunsballeJM, DjurhuusJC. Clinical options for imipramine in the management of urinary incontinence. Urol Res, 2001; 29:118–125.
25.
O'NeilBB, PressonA, GannonJ, et al.Climacturia after definitive treatment of prostate cancer. J Urol, 2014; 191:159–163.
26.
MillerDC, WeiJT, DunnRL, et al.Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: Potential influence of sexual motivation and/or indifference. Urology, 2006; 68:166–171.
27.
GulleyJL, Aragon-ChingJB, SteinbergSM, et al.Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 2008; 180:1432–1437.
28.
NgE, WooHH, TurnerS, LeongE, JacksonM, SpryN. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: Observations from a prospective study in men undergoing intermittent androgen suppression. J Urol, 2012; 187:2162–2166.
29.
CappelleriJC, RosenRC. The Sexual Health Inventory for Men (SHIM): A 5-year review of research and clinical experience. Int J Impot Res, 2005; 17:307–319.
30.
LitwinMS, HaysRD, FinkA, GanzPA, LeakeB, BrookRH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care, 1998; 36:1002–1012.
31.
LatiniDM, HartSL, CoonDW, KnightSJ. Sexual rehabilitation after localized prostate cancer: current interventions and future directions. Cancer J, 2009; 15:34–40.
32.
AdlerN, PageNEK, eds. Institute of Medicine (IOM). Cancer care for the whole patient: Meeting psychosocial health needs. Washington, DC: The National Academies Press, 2008.
33.
HedestigO, SandmanPO, TomicR, WidmarkA. Living after radical prostatectomy for localized prostate cancer: A qualitative analysis of patient narratives. Acta Oncol, 2005; 44:679–686.
34.
HedestigO, SandmanPO, TomicR, WidmarkA. Living after external beam radiotherapy of localized prostate cancer: A qualitative analysis of patient narratives. Cancer Nurs, 2005; 28:310–317.
35.
KatzA. Quality of life for men with prostate cancer. Cancer Nurs, 2007; 30:302–308.
36.
CouperJ, BlochS, LoveA, MacveanM, DuchesneGM, KissaneD. Psychosocial adjustment of female partners of men with prostate cancer: A review of the literature. Psychooncology, 2006; 15:937–953.
37.
CouperJW, BlochS, LoveA, DuchesneG, MacveanM, KissaneDW. The psychosocial impact of prostate cancer on patients and their partners. Med J Aust, 2006; 185:428–432.
38.
BoehmerU, ClarkJA. Communication about prostate cancer between men and their wives. J Fam Pract, 2001; 50:226–231.
39.
WoottenAC, BurneyS, ForoudiF, FrydenbergM, ColemanG, NgKT. Psychological adjustment of survivors of localised prostate cancer: investigating the role of dyadic adjustment, cognitive appraisal and coping style. Psychooncology, 2007; 16:994–1002.
40.
MontorsiF, AdaikanG, BecherE, et al.Summary of the recommendations on sexual dysfunctions in men. J Sex Med, 2010; 7:3572–3588.
41.
MazzolaC, MulhallJP. Penile rehabilitation after prostate cancer treatment: Outcomes and practical algorithm. Urol Clin North Am, 2011; 38:105–118.
42.
RainaR, PahlajaniG, AgarwalA, ZippeCD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int, 2007; 100:1317–1321.
American Association of Sex Educators, Counselors, and Therapists (AASECT) Available at www.aasect.org Last accessed June3, 2014.
45.
HaboubiNY, SchofieldPF, RowlandPL. The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol, 1988; 83:1140–1144.
46.
ChoeKS, JaniAB, LiauwSL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: How significant is the bleeding toxicity?. Int J Radiat Oncol Biol Phys, 2010; 76:755–760.
OdrazkaK, DolezelM, VanasekJ, et al.Time course of late rectal toxicity after radiation therapy for prostate cancer. Prostate Cancer Prostatic Dis, 2010; 13:138–143.
49.
ZelefskyMJ, LevinEJ, HuntM, et al.Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys, 2008; 70:1124–1129.
50.
SheetsNC, GoldinGH, MeyerAM, et al.Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA, 2012; 307:1611–1620.
51.
FellinG, FiorinoC, RancatiT, et al.Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: Results of a large multicenter observational study. Radiother Oncol, 2009; 93:197–202.
52.
VavassoriV, FiorinoC, RancatiT, et al.Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: Results of a prospective multicenter study. Int J Radiat Oncol Biol Phys, 2007; 67:1401–1410.
53.
SkwarchukMW, JacksonA, ZelefskyMJ, et al.Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys, 2000; 47:103–113.
54.
ValdagniR, VavassoriV, RancatiT, et al.Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiother Oncol, 2012; 103:252–255.
55.
PeetersST, HeemsbergenWD, van PuttenWL, et al.Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys, 2005; 61:1019–1034.
56.
WillettCG, OoiCJ, ZietmanAL, et al.Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys, 2000; 46:995–998.
57.
CheungR, TuckerSL, YeJS, et al.Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2004; 58:1513–1519.
58.
HamstraDA, StenmarkM, RitterT, et al.Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2013Apr1; 85:1246–1253.
59.
KushwahaRS, HayneD, VaizeyCJ, WrighthamE, PayneH, BoulosPB. Physiologic changes of the anorectum after pelvic radiotherapy for the treatment of prostate and bladder cancer. Dis Colon Rectum, 2003; 46:1182–1188.
60.
YeohEE, HollowayRH, FraserRJ, et al.Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. Am J Gastroenterol, 2004; 99:361–369.
61.
SatoY, TakayamaT, SagawaT, et al.Argon plasma coagulation treatment of hemorrhagic radiation proctopathy: The optimal settings for application and long-term outcome. Gastrointest Endosc, 2011; 73:543–549.
62.
de BonoJS, LogothetisCJ, MolinaA, et al.Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 2011; 364:1995–2005.
63.
LevineGN, D'AmicoAV, BergerP, et al.Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin, 2010; 60:194–201.
64.
KeatingNL, O'MalleyA, FreedlandSJ, SmithMR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst, 2012; 104:1518–1523.
65.
SaylorPJ, KeatingNL, FreedlandSJ, SmithMR. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs, 2011; 71:255–261.
66.
Braga-BasariaM, DobsAS, MullerDC, et al.Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol, 2006; 24:3979–3983.
67.
AutorinoR, PerdonaS, D'ArmientoM, et al.Gynecomastia in patients with prostate cancer: Update on treatment options. Prostate Cancer Prostatic Dis, 2006; 9:109–114.
68.
ChenAC, PetrylakDP. Complications of androgen-deprivation therapy in men with prostate cancer. Curr Urol Rep, 2005; 6:210–216.
69.
SaylorPJ, LeeRJ, SmithMR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol, 2011; 29:3705–3714.
70.
SaylorPJ, KeatingNL, SmithMR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med, 2009; 24:S389–394.
71.
SaylorPJ, SmithMR. Bone health and prostate cancer. Prostate Cancer Prostatic Dis., 2010Mar; 13:20–27.
72.
GreenspanSL, NelsonJB, TrumpDL, ResnickNM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med, 2007; 146:416–424.
73.
ShahinianVB, KuoYF, FreemanJL, GoodwinJS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med, 2005; 352:154–164.
74.
SaadF, AbrahamssonPA, MillerK. Preserving bone health in patients with hormone-sensitive prostate cancer: The role of bisphosphonates. BJU Int, 2009; 104:1573–1579.
75.
SaadF, GleasonDM, MurrayR, et al.A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002; 94:1458–1468.
76.
SmithMR, EgerdieB, Hernandez TorizN, et al.Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med, 2009; 361:745–755.
77.
LeeRJ, SaylorPJ, SmithMR. Treatment and prevention of bone complications from prostate cancer. Bone, 2011; 48:88–95.
78.
KouriefsC, GeorgiouM, RaviR. Hot flushes and prostate cancer: Pathogenesis and treatment. BJU Int, 2002; 89:379–383.
79.
McLeodDG, IversenP. Gynecomastia in patients with prostate cancer: A review of treatment options. Urology, 2000; 56:713–720.
NeuwahlS, ThompsonK, FraherE, RickettsT. HPRI data tracks. Urology workforce trends. Bull Am Coll Surg, 2012; 97:46–49.
82.
MaoJJ, BowmanMA, StrickerCT, et al.Delivery of survivorship care by primary care physicians: The perspective of breast cancer patients. J Clin Oncol, 2009; 27:933–938.
83.
SalsbergES, ForteGJ. Trends in the physician workforce, 1980–2000. Health Aff (Millwood), 2002; 21:165–173.
84.
CheungWY, NevilleBA, CameronDB, CookEF, EarleCC. Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol, 2009; 27:2489–2495.
85.
Del GiudiceME, GrunfeldE, HarveyBJ, PiliotisE, VermaS. Primary care physicians' views of routine follow-up care of cancer survivors. J Clin Oncol, 2009; 27:3338–3345.
86.
GrunfeldE. Looking beyond survival: how are we looking at survivorship?. J Clin Oncol, 2006; 24:5166–5169.
87.
GrunfeldE, LevineMN, JulianJA, et al.Randomized trial of long-term follow-up for early-stage breast cancer: A comparison of family physician versus specialist care. J Clin Oncol, 2006; 24:848–855.
88.
HorningSJ. Follow-up of adult cancer survivors: new paradigms for survivorship care planning. Hematol Oncol Clin North Am, 2008; 22:201–210, v.
89.
SnyderCF, EarleCC, HerbertRJ, NevilleBA, BlackfordAL, FrickKD. Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med, 2008; 23:254–259.
90.
SnyderCF, FrickKD, KantsiperME, et al.Prevention, screening, and surveillance care for breast cancer survivors compared with controls: Changes from 1998 to 2002. J Clin Oncol, 2009; 27:1054–1061.
91.
LoebS, FengZ, RossA, TrockBJ, HumphreysEB, WalshPC. Can we stop prostate specific antigen testing 10 years after radical prostatectomy?. J Urol, 2011; 186:500–505.
92.
BennettAV, JensenRE, BaschE. Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin, 2012; 62:337–347.
93.
SkolarusTA, Holmes-RovnerM, HawleyST, et al.Monitoring quality of life among prostate cancer survivors: the feasibility of automated telephone assessment. Urology, 2012; 80:1021–1026.
FilocamoMT, Li MarziV, Del PopoloG, et al.Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. Eur Urol, 2005; 48:734–738.
96.
GriseP, ThurmanS. Urinary incontinence following treatment of localized prostate cancer. Cancer Control, 2001; 8:532–539.
97.
Van KampenM, De WeerdtW, Van PoppelH, De RidderD, FeysH, BaertL. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: A randomised controlled trial. Lancet, 2000; 355:98–102.
98.
MooreKN, SchiemanS, AckermanT, DzusHY, MetcalfeJB, VoaklanderDC. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. Urology, 2004; 63:150–154.
99.
AboseifSR, O'ConnellHE, UsuiA, McGuireEJ. Collagen injection for intrinsic sphincteric deficiency in men. J Urol, 1996; 155:10–13.
LitwillerSE, KimKB, FonePD, WhiteRW, StoneAR. Post-prostatectomy incontinence and the artificial urinary sphincter: A long-term study of patient satisfaction and criteria for success. J Urol, 1996; 156:1975–1980.
102.
VennSN, GreenwellTJ, MundyAR. The long-term outcome of artificial urinary sphincters. J Urol, 2000; 164(3 Pt 1):702–706; discussion 706–707.
103.
SternJA, ClemensJQ, TiplitskySI, MatschkeHM, JainPM, SchaefferAJ. Long-term results of the bulbourethral sling procedure. J Urol, 2005; 173:1654–6.
104.
ComiterCV. The male perineal sling: intermediate-term results. Neurourol Urodyn, 2005; 24:648–653.
105.
ZippeCD, JhaveriFM, KleinEA, et al.Role of Viagra after radical prostatectomy. Urology, 2000; 55:241–245.
106.
MeulemanEJ, MuldersPF. Erectile function after radical prostatectomy: A review. Eur Urol, 2003; 43:95–101; discussion 101–102.
107.
UrciuoliR, CantisaniTA, CarliniM, GiugliettiM, BottiFM. Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database Syst Rev, 2004:CD001784.
108.
BanielJ, IsrailovS, SegenreichE, LivnePM. Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int, 2001; 88:58–62.
109.
ValeJ. Erectile dysfunction following radical therapy for prostate cancer. Radiother Oncol, 2000; 57:301–305.
110.
CarsonCC, MulcahyJJ, GovierFE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol, 2000; 164:376–380.
111.
LarsonDW, ChrouserK, Young-FadokT, NelsonH. Rectal complications after modern radiation for prostate cancer: a colorectal surgical challenge. J Gastrointest Surg, 2005; 9:461–466.
112.
LoprinziCL, BartonDL, CarpenterLA, et al.Pilot evaluation of paroxetine for treating hot flashes in men. Mayo Clin Proc, 2004; 79:1247–1251.
113.
MoraskaAR, AthertonPJ, SzydloDW, et al.Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol, 2010; 8:128–132.
114.
FilshieJ, BoltonT, BrowneD, AshleyS. Acupuncture and self acupuncture for long-term treatment of vasomotor symptoms in cancer patients–audit and treatment algorithm. Acupunct Med, 2005; 23:171–180.
115.
HammarM, FriskJ, GrimasO, HookM, SpetzAC, WyonY. Acupuncture treatment of vasomotor symptoms in men with prostatic carcinoma: a pilot study. J Urol, 1999; 161:853–856.
116.
McLeodN, HuynhCC, RashidP. Osteoporosis from androgen deprivation therapy in prostate cancer treatment. Aust Fam Physician, 2006; 35:243–245.
117.
DiamondTH, BucciJ, KersleyJH, AslanP, LynchWB, BryantC. Osteoporosis and spinal fractures in men with prostate cancer: Risk factors and effects of androgen deprivation therapy. J Urol, 2004; 172:529–532.
118.
LiptonA, SmallE, SaadF, et al.The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: A comparison to pamidronate. Cancer Invest, 2002; 20Suppl 2:45–54.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
